Schneeberger Daniel — SEC Form 4 filings
SEC reporting owner CIK 1861120. 16 Form 4 filings on record with FilingPulse; latest filed 2026-09-16.
Transaction summary — filings shown
Covers all 16 filings on record, filed 2025-04-11 to 2026-09-16. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 46 legs across 13 filings — 4,840,344 shares, $21,046,845 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 3 legs across 1 filing — 5,389,264 shares, $95,659,436 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 12.
- Largest priced transaction: sale of 4,391,237 shares @ $17.75 ($77,944,457) in Keros Therapeutics, Inc., filed 2025-10-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | 10% owner | 4 | 5 legs · 934,258 sh · $9,464,512 | 3 legs · 5,389,264 sh · $95,659,436 | 12 |
| TENAX THERAPEUTICS, INC. (TENX) | 10% owner | 3 | 7 legs · 2,696,200 sh · $4,800,057 | — | — |
| Rallybio Corp (RLYB) | 10% owner | 4 | 14 legs · 302,473 sh · $4,229,263 | — | — |
| NextCure, Inc. (NXTC) | 10% owner | 2 | 13 legs · 346,761 sh · $1,711,833 | — | — |
| InMed Pharmaceuticals Inc. (INM) | 10% owner | 3 | 7 legs · 560,652 sh · $841,179 | — | — |
Form 4 filings — Schneeberger Daniel
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-16 | 4 | InMed Pharmaceuticals Inc. (INM) jointly with ADAR1 Capital Management, LLC | Purchase (P): 28,505 @ $1.29 · Purchase (P): 54,256 @ $1.30 · Purchase (P): 8,340 @ $1.29 | EDGAR |
| 2026-09-08 | 4 | TENAX THERAPEUTICS, INC. (TENX) jointly with ADAR1 Capital Management, LLC | Purchase (P): 900,000 @ $1.78 | EDGAR |
| 2026-09-02 | 4 | TENAX THERAPEUTICS, INC. (TENX) jointly with ADAR1 Capital Management, LLC | Purchase (P): 403,571 @ $1.79 · Purchase (P): 179,058 @ $1.80 · Purchase (P): 187,704 @ $1.80 | EDGAR |
| 2026-08-24 | 4 | TENAX THERAPEUTICS, INC. (TENX) jointly with ADAR1 Capital Management, LLC | Purchase (P): 202,124 @ $1.78 · Purchase (P): 716,369 @ $1.77 · Purchase (P): 107,374 @ $1.75 | EDGAR |
| 2026-08-03 | 4 | NextCure, Inc. (NXTC) jointly with ADAR1 Capital Management, LLC | Purchase (P): 50,000 @ $4.97 · Purchase (P): 20,000 @ $5 · Purchase (P): 20,000 @ $5 · Purchase (P): 25,000 @ $4.81 · Purchase (P): 100,000 @ $4.90 · Purchase (P): 77,850 @ $4.96 · +3 more | EDGAR |
| 2026-07-29 | 4 | NextCure, Inc. (NXTC) jointly with ADAR1 Capital Management, LLC | Purchase (P): 7,798 @ $5.00 · Purchase (P): 6,400 @ $4.95 · Purchase (P): 1,810 @ $5 · Purchase (P): 1,600 @ $5 | EDGAR |
| 2026-07-17 | 4 | InMed Pharmaceuticals Inc. (INM) jointly with ADAR1 Capital Management, LLC | Purchase (P): 1,000 @ $1.55 | EDGAR |
| 2026-05-21 | 4 | InMed Pharmaceuticals Inc. (INM) jointly with ADAR1 Capital Management, LLC | Purchase (P): 68,551 @ $1.60 · Purchase (P): 200,000 @ $1.56 · Purchase (P): 200,000 @ $1.50 | EDGAR |
| 2026-05-20 | 4 | Rallybio Corp (RLYB) jointly with ADAR1 Capital Management, LLC | Purchase (P): 6,009 @ $13.98 · Purchase (P): 10,000 @ $13.98 · Purchase (P): 200 @ $13.80 | EDGAR |
| 2026-05-15 | 4 | Rallybio Corp (RLYB) jointly with ADAR1 Capital Management, LLC | Purchase (P): 4,081 @ $13.80 · Purchase (P): 75,178 @ $14 · Purchase (P): 100 @ $13.80 · Purchase (P): 200 @ $13.95 | EDGAR |
| 2026-05-13 | 4 | Rallybio Corp (RLYB) jointly with ADAR1 Capital Management, LLC | Purchase (P): 5,100 @ $14.00 · Purchase (P): 25,000 @ $14 · Purchase (P): 19,900 @ $14 · Purchase (P): 800 @ $13.83 | EDGAR |
| 2026-05-06 | 4 | Rallybio Corp (RLYB) jointly with ADAR1 Capital Management, LLC | Purchase (P): 3,900 @ $13.90 · Purchase (P): 116,904 @ $13.97 · Purchase (P): 35,101 @ $14.00 | EDGAR |
| 2025-10-15 | 4 | Keros Therapeutics, Inc. (KROS) jointly with ADAR1 Capital Management, LLC, ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC | Sale (S): 4,391,237 @ $17.75 · Sale (S): 254,669 @ $17.75 · Sale (S): 743,358 @ $17.75 | EDGAR |
| 2025-06-24 | 4 | Keros Therapeutics, Inc. (KROS) jointly with ADAR1 Capital Management, LLC, ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC | Option exercise/expiry (X): 100 @ $60 · Option exercise/expiry (X): 1,400 @ $70 · Option exercise/expiry (X): 200 @ $70 · Option exercise/expiry (X): 1 (derivative) @ $0 · Option exercise/expiry (X): 14 (derivative) @ $0 · Option exercise/expiry (X): 2 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Keros Therapeutics, Inc. (KROS) jointly with ADAR1 Capital Management, LLC, ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC | Code (E): 300 (derivative) @ $0 · Code (E): 836 (derivative) @ $0 · Code (E): 178 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | Keros Therapeutics, Inc. (KROS) jointly with ADAR1 Capital Management, LLC, ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC | Purchase (P): 18,560 @ $9.40 · Purchase (P): 16,365 @ $9.40 · Purchase (P): 325,000 @ $9.86 · Purchase (P): 500,000 @ $10.33 · Purchase (P): 74,333 @ $10.33 · Other (J): 325,000 (derivative) · +2 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1861120 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →